尊龙凯时

关于尊龙凯时
研发服务
服务平台
客户中心
新闻资讯
投资者关系
人力资源
EN
×
EN

  • 营业咨询

    中国：

    Email: marketing@medicilon.com.cn

    营业咨询专线：400-780-8018

    （仅限服务咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    外洋：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jul 06,2023
设计合成一系列用于治疗胃癌的多靶点受体酪氨酸激酶抑制剂，并举行生物学评价。其中药代动力学剖析通过尊龙凯时举行
Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric cancer. The pharmacokinetical profile (PK) of 8f was tested in SD rats. Compound 8f showed an acceptable half-time of 3 h and displayed moderate maximum concentrations, which is enough to meet the concentration of the compound 8f to exert its efficacy in vivo. The pharmacokinetic analysis was performed by the testing service provided by Medicilon.
审查更多
设计合成一系列用于治疗胃癌的多靶点受体酪氨酸激酶抑制剂，并举行生物学评价。其中药代动力学剖析通过尊龙凯时举行
Jul 06,2023
表观遗传修饰，如DNA甲基化，在遗传信息的表达中施展着主要作用。DNA甲基转移酶维持DNA甲基化，是肿瘤化疗的一个有吸引力的靶点
Epigenetic modification, like DNA methylation, plays a major role in the expression of genetic information. The DNA methyltransferases (DNMTs), maintain DNA methylation, is an attractive target for tumor chemotherapy. WK-23 displays a good inhibitory effect on human DNMT1 with an IC50 value of 5.0??M. The PK profile of WK-23 was obtained with quite satisfying oral bioavailability and elimination half-life. In vivo pharmacokinetic properties of WK-22, WK-23, WK-27, and DC_517 were performed by Medicilon.
审查更多
表观遗传修饰，如DNA甲基化，在遗传信息的表达中施展着主要作用。DNA甲基转移酶维持DNA甲基化，是肿瘤化疗的一个有吸引力的靶点
Jul 06,2023
FBPase是与肿瘤和2型糖尿病相关的一个有远景的靶点�；衔颳8对FBPase体现出高选择性。W8的药代动力学研究通过尊龙凯时举行
Fructose-1,6-bisphosphatase (FBPase) is a promising target associated with cancer and type 2 diabetes. Compounds W8 and W8k exhibit high selectivity against FBPase and W8 effectively reduces blood glucose in an Institute of Cancer Research (ICR) mice model and dose-dependent inhibition of glucose production in a primary mouse hepatocyte model. The pharmacokinetic studies of W8 and its leaving group saccharin were performed by Medicilon.
审查更多
FBPase是与肿瘤和2型糖尿病相关的一个有远景的靶点�；衔颳8对FBPase体现出高选择性。W8的药代动力学研究通过尊龙凯时举行
Jul 06,2023
药物发明中的挑战之一是识别高质量的先导化合物。此研究中PK效果批注L12可作为针对PDE5的先导化合物，进一步研究和开发。L12的PK剖析通过尊龙凯时举行
Scaffold hopping refers to computer-aided screening for active compounds with different structures against the same receptor to enrich privileged scaffolds, which is a topic of high interest in organic and medicinal chemistry. One of the biggest challenges in drug discovery is to identify high-quality hit and lead compounds. Lead L12 had an IC50 of 8.7 nM and exhibited a different binding pattern in its crystal structure with PDE5 from the famous starting drug tadalafil, and PK results indicate that L12 could be used as a promising lead for further development. Pharmacokinetic properties of L12 were analyzed by Medicilon.
审查更多
药物发明中的挑战之一是识别高质量的先导化合物。此研究中PK效果批注L12可作为针对PDE5的先导化合物，进一步研究和开发。L12的PK剖析通过尊龙凯时举行
Jul 06,2023
ANO1是一个潜在的镇痛靶点。DFBTA是一种有用的ANO1抑制剂，具有优异的药代动力学特征。体内PK测试通过尊龙凯时举行
Current pain management is largely limited to opioids and non-steroidal anti-inflammatory drugs. Developing new analgesic drugs remains important to address the unmet medical needs of chronic pain patients. Calcium-activated chloride channel anoctamin-1 (ANO1) is a potential analgesic target. DFBTA is a potent inhibitor with the IC50 of 24 nM. DFBTA shows very weak cytotoxicity, cardiotoxicity, and acute toxicity, as well as excellent pharmacokinetics properties with oral bioavailability >75% and little brain penetration (<1.5% brain/plasma). In vivo PK were tested by Medicilon.
审查更多
ANO1是一个潜在的镇痛靶点。DFBTA是一种有用的ANO1抑制剂，具有优异的药代动力学特征。体内PK测试通过尊龙凯时举行
Jul 06,2023
XY153是一种有潜力的先导化合物，可用于开发针对急性髓系白血病。XY153在体外具有优异的代谢稳固性。所有肝微粒体测定均通过尊龙凯时举行
Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The representative Compound 8l (XY153), a novel BD2-selective BET inhibitor, potently binds to BRD4 BD2 with an IC50 value of 0.79 nM. XY153 displayed potent antiproliferative activity against multiple tumor cell lines. XY153 also demonstrated good metabolic stability in vitro. These data indicate that XY153 may serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML). All liver microsome assays were performed by Medicilon.
审查更多
XY153是一种有潜力的先导化合物，可用于开发针对急性髓系白血病。XY153在体外具有优异的代谢稳固性。所有肝微粒体测定均通过尊龙凯时举行
Jul 06,2023
Y180是一种口服Mpro抑制剂，可有用对抗野生型SARS-CoV-2及其变种。Y180在小鼠、大鼠和狗中具有优异的PK特征
Y180, an orally available Mpro inhibitor, is effective against wild-type SARS-CoV-2 and variants. Y180 displayed satisfying PK properties in mice, rats and dogs, with oral bioavailabilities of 92.9%, 31.9% and 85.7%, respectively. The in vivo PK properties of Y180 were evaluated. All procedures related to animal handling, care and treatment in PK studies were performed according to approved guidelines. The PK studies were approved by the Ethics Committee of Medicilon.
审查更多
Y180是一种口服Mpro抑制剂，可有用对抗野生型SARS-CoV-2及其变种。Y180在小鼠、大鼠和狗中具有优异的PK特征
Jul 06,2023
Ulotaront是一种具有5-HT1A激动剂活性的TAAR1 激动剂，可用于治疗精神破碎症。Ulotaront在大鼠脑中的漫衍和在猴血浆中的PK研究通过尊龙凯时举行
Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity currently in clinical development for the treatment of Schizophrenia. Ulotaront exhibits rapid absorption, greater than 70% bioavailability, and good penetration across the blood–brain barrier in preclinical species. The distribution of Ulotaront to rat brain was conducted at Medicilon/MPI Preclinical Research. Ulotaront monkey plasma PK was conducted at Medicilon/MPI Preclinical Research.
审查更多
Ulotaront是一种具有5-HT1A激动剂活性的TAAR1 激动剂，可用于治疗精神破碎症。Ulotaront在大鼠脑中的漫衍和在猴血浆中的PK研究通过尊龙凯时举行
Jul 06,2023
基于构效关系剖析，合成了一种结构简化但具有优异防污活性的化合物。优化后的化合物通过尊龙凯时合成
Biofouling poses one of the most serious problems to marine industry and aquaculture development. Five structurally similar compounds were isolated from the crude extract of a marine Streptomyces strain. Antifouling activities of these compounds and four other structurally-related compounds isolated from another marine Streptomyces species were compared to generate structure–activity relationship data. Based on structure–activity relationship analysis, another compound with a simplified structure but excellent antifouling activities was synthesized. The optimized compound was synthesized by Medicilon.
审查更多
基于构效关系剖析，合成了一种结构简化但具有优异防污活性的化合物。优化后的化合物通过尊龙凯时合成
Jul 06,2023
开发和验证大鼠血浆中Nobiliside A定量的LC/MS/MS要领
Nobiliside A, a new triterpene glycoside, exhibits some biological activities including antifungal and cytotoxic effects. A LC/MS/MS method was developed and validated for determination of Nobiliside A in rat plasma, would prove to be useful for other pharmacokinetic assessments. Male SD rats were housed in Medicilon animal facility. The animal experiments of the present study were approved by IACUC of Medicilon and were carried out in accordance with the SOPs of the facility.
审查更多
开发和验证大鼠血浆中Nobiliside A定量的LC/MS/MS要领
×
搜索验证
点击切换
网站地图
友情链接：吕氏贵宾会  尊龙凯时  凯时人生就是搏  ca88官网  z6com尊龙凯时代理  贝斯特全球最奢华  庄闲官网  古天乐太阳娱乐集团  k1体育  yp街机电子游戏  沙巴官网  沙巴官网  cq9电子  918博天娱乐庄闲  曾氏贵宾会